EMD Millipore, the life science business of Merck KGaA, has Singulex Inc., a developer and provider of single molecule counting (SMC) technology for clinical diagnostics and scientific discovery, have formed an agreement under which EMD Millipore will control and manage the Singulex Life Science Research business, one of Singulex's three areas of business. Under the terms of the agreement, EMD Millipore will pay Singulex an upfront payment, royalties, and additional payments based upon achievement of certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize Singulex's proprietary SMC technology for research applications worldwide.

Singulex's SMC technology is a patented technology combining signal enhancement and background reduction coupled with low-volume sampling to achieve ultra-high sensitivity protein detection. Singulex will continue to operate a large clinical lab testing business and an emerging in vitro diagnostics business based on SMC assays. Financial and other terms of the deal were not disclosed.

Source: Singulex